Literature DB >> 33955309

Glycosylated hemoglobin as a predictor of mortality in severe pneumonia by COVID-19.

Jesús Salvador Sánchez Díaz1, Karla Gabriela Peniche Moguel1, Eduardo Alberto González Escudero2, Luis Del Carpio Orantes3, Enrique Monares Zepeda4, Orlando Rubén Perez Nieto5, Eder Ivan Zamarron Lopez6, Ernesto Deloya Tomas5, Fernando Enrique Estrada Gonzalez1, Jesús Díaz Torres1, Diego Escarraman Martinez7, Manuel Alberto Guerrero Gutierrez8.   

Abstract

OBJECTIVE: Determine whether the levels of glycated hemoglobin (HbA1c) measured on admission to the intensive care unit (ICU) are associated with mortality in patients with severe SARS-CoV-2 pneumonia with invasive mechanical ventilation.
DESIGN: Cohort study, retrospective, observational. A single center. PLACE: ICU of a second-level care hospital. PATIENTS: Severe SARS-CoV-2 pneumonia confirmed with IMV since admission to the ICU.
INTERVENTIONS: none.
RESULTS: A total of 56 patients with severe pneumonia, confirmed with SARS-CoV-2, all with IMV. The group with HbA1c <6.5% included 32 (57.14%) patients and the group with HbA1c ≥6.5% included 24 (42.86%) patients and the mortality rate in ICU was 43.8% and 70.8%, respectively, with p = 0.04. Predictors of mortality at 28 days in ICU were DHL >500 U/L, OR 3.65 (95% CI 1.18-11.29), HbA1c ≥6.5%, OR 3.12 (95% CI 1.01-9.6), SAH, OR 3.12 (95% CI 1.01-9.5), use of vasopressor, OR 0.2 (95% CI 0.05-0.73), diabetes was not statistically significant.
CONCLUSION: The 28-day probability of survival in patients with severe SARS-CoV-2 pneumonia with IMV in the ICU is lower when the HbA1c level is ≥6.5% on admission.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; Severe pneumonia; glycosylated hemoglobin; mechanical ventilation; mortality

Year:  2021        PMID: 33955309     DOI: 10.1080/17476348.2021.1926988

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  1 in total

1.  Glycaemic variability is associated with all-cause mortality in COVID-19 patients with ARDS, a retrospective subcohort study.

Authors:  Bojan Hartmann; Marlo Verket; Paul Balfanz; Niels-Ulrik Hartmann; Malte Jacobsen; Julia Brandts; Michael Dreher; Nils Kossack; Dennis Häckl; Nikolaus Marx; Dirk Müller-Wieland
Journal:  Sci Rep       Date:  2022-06-14       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.